Next-Generation Gynecological Cancer Diagnostics Global Market Report 2024

The next-generation gynecological cancer diagnostics market size has grown rapidly in recent years. It will grow from $2.39 billion in 2023 to $2.68 billion in 2024 at a compound annual growth rate (CAGR) of 12.3%. The expansion witnessed in the past era can be ascribed to advancements in genomic research, intensified awareness and screening programs, a rise in the prevalence of gynecological cancers, improvements in biopsy techniques, elevated investments in clinical trials, and increased funding for research.

The next-generation market for gynecological cancer diagnostics is poised for significant expansion, projected to reach $4.07 billion by 2028 with a robust Compound Annual Growth Rate (CAGR) of 11.0%. This growth is fueled by key factors including the adoption of precision medicine and targeted therapies, the integration of artificial intelligence (AI), the increasing popularity of liquid biopsy, the expansion of point-of-care testing, widespread implementation of 3D imaging, and the growing role of telemedicine in cancer care. Noteworthy trends in this forecast period encompass patient-centric diagnostics, the use of comprehensive biomarker panels, integration of wearable devices, collaborative efforts through consortia, and advancements in imaging modalities.

The upward trajectory of the market is significantly influenced by the rising incidence of gynecological malignancies, affecting reproductive organs such as the cervix, uterus, ovaries, fallopian tubes, and vulva. Next-generation gynecological cancer diagnostics are instrumental in addressing these malignancies through early cancer cell detection, facilitating targeted treatments, and ultimately improving overall patient outcomes. As of February 2023, the National Cancer Institute projected that 13,960 American women would face an aggressive cervical cancer diagnosis, with an expected 4,310 fatalities in the same year. These figures underscore the urgent need for advanced diagnostic solutions, with an annual incidence of 7.7 new cases per 100,000 women and an annual death rate of 2.2 per 100,000 females. Consequently, the rising prevalence of gynecological malignancies serves as a substantial driver propelling the growth of the next-generation gynecological cancer diagnostics market.

The growth of the gynecological cancer diagnostics market is anticipated to be fueled by the increasing adoption of personalized medicine. This innovative healthcare approach tailors medical treatment and interventions to the unique characteristics of each patient. Personalized medicine enhances precision diagnosis by considering individual genetic and molecular variations, leading to more accurate and targeted therapies. This approach not only predicts treatment responses but also reduces adverse effects and enables early detection of genetic predispositions. In 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 of them) classified as personalized medicines by the Personalized Medicine Coalition (PMC). Consequently, the growing adoption of personalized medicine emerges as a driving force behind the expansion of the next-generation gynecological cancer diagnostics market.

Leading companies in the next-generation gynecological cancer diagnostics market are actively innovating by introducing cutting-edge products, such as AI-enabled women's health ultrasound systems, to secure a competitive advantage. Ultrasound systems are pivotal medical imaging devices that utilize high-frequency sound waves to generate visual representations of internal body structures. For example, in February 2023, Samsung Electronics Co. Ltd., a South Korea-based consumer electronics giant, launched the HERA W10 Elite. This women's health ultrasound system incorporates artificial intelligence (AI) tools and clinical applications tailored for Obstetrics and Gynecology. The HERA W10 Elite delivers advanced 2D and 3D visualizations of microcirculatory and slow blood, featuring an Advanced MV-Flow capability, a larger organic light-emitting diode (OLED) display, and enhanced AI capabilities such as HeartAssist, ViewAssist, and BiometryAssist. Engineered for enhanced diagnostic insights, the HERA W10 Elite aims to revolutionize Obstetrics and Gynecology through sophisticated image processing and an ergonomic-friendly design.

Major players in the gynecological cancer diagnostics market are strategically developing novel products such as cervical cancer vaccines to stay ahead in the competitive landscape. Vaccines are biological preparations that confer active acquired immunity to specific diseases. For instance, in July 2023, Serum Institute of India Pvt. Ltd., a prominent Indian biotechnology company, introduced Cervavac, the nation's first domestically-produced vaccine providing protection against cervical cancer. Cervavac guards against the Human Papilloma Virus (HPV), the primary cause of cervical cancer, and is accessible to both men and women. Operating prophylactically, Cervavac stimulates the immune system to prevent HPV infection, offering cross-protection against multiple high-risk HPV types. With proven efficacy against HPV types 16 and 18, Cervavac is priced affordably at 200 to 400 rupees (approximately $2.50 to $5), ensuring accessibility, particularly for marginalized communities. This initiative contributes to making cervical cancer prevention more cost-effective in India.

In August 2021, Illumina Inc., a US-based biotechnology firm, executed the acquisition of Grail for an undisclosed amount. This strategic move significantly expands, diversifies, and enriches Illumina's cancer diagnostics portfolio by incorporating early detection tests for multiple cancers. Grail, a US-based biotechnology company, is the creator of Galleri, a multi-cancer early-detection blood test that diagnoses vaginal and uterine cancer, further reinforcing Illumina's position in the evolving landscape of cancer diagnostics.

Major companies operating in the next-generation gynecological cancer diagnostics market report are F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Janssen Global Services LLC, Siemens Healthcare GmbH, Agena Bioscience Inc., Koninklijke Philips N.V., Becton, Dickinson and Company, GE HealthCare Technologies Inc., Laboratory Corporation Of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Konica Minolta Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Qiagen N.V., ARUP Laboratories, Almac Group, BGI Genomics Co Ltd, OPKO HEALTH Inc., BGI Genomics Co. Ltd., Myriad Genetics Inc., Fulgent Genetics Inc., Cepheid, Invitae Corporation, Centogene NV.

North America was the largest region in the next-generation gynecological cancer diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation gynecological cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation gynecological cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of next-generation gynecological cancers comprise cervical cancer, ovarian cancer, uterine cancer, vaginal cancer, and vulvar cancer. Cervical cancer specifically occurs in the cells of the cervix, the lower segment of the uterus. Various diagnostic functions are performed, including therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis. These functions utilize a range of technologies such as next-generation sequencing, QPCR and multiplexing, lab-on-a-chip (LOAC), reverse transcriptase-PCR (RT-PCR), protein microarrays, and DNA microarrays. Applications of these technologies span biomarker development, circulating tumor cell (CTC) analysis, proteomic analysis, epigenetic analysis, and genetic analysis. The end users of these diagnostics encompass hospitals and ambulatory centers, diagnostic laboratories, and academic and research institutes.

The next-generation gynecological cancer diagnostics market research report is one of a series of new reports that provides next-generation gynecological cancer diagnostics market statistics, including next-generation gynecological cancer diagnostics industry global market size, regional shares, competitors with a next-generation gynecological cancer diagnostics market share, detailed next-generation gynecological cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation gynecological cancer diagnostics industry. This next-generation gynecological cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next-generation gynecological cancer diagnostics market includes revenues earned by entities by providing blood tests, next-generation sequencing, imaging tests, biopsy and pathology, minimally invasive procedures, personalized medicine, and molecular profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.